Sender:
`
`Sent:
`Recipient:
`
`Lehr Mary </O=CAR1ER-
`W ALLACE/OU=CRANMAJL/CN=RECIPIENTS/CN=EXCHANGE/CN=MLEHR>
`Tuesday, November 11, 2003 2:56:40 PM
`Balwani Gul <GBalwani@medpointepharma.com>;Cupo Frank
`<FCupo@medpointepharma. com>;Dang Grace <gdang@medpointeinc. com> ;He
`Weixuan <WHe@medpointepharma.com>;Mortko Henry
`<HMortko@medpointepharma.com>; Yayac Cindy <CYayac@medpointepharma.com>
`Cc:
`D'Addio Alex <ADAddio@medpointepharma.com>
`Subject:
`Wednesday Cough/Cold Meeting
`Attachments: Projects2.xls
`
`In place ofthe Wednesday Cough/Cold meeting this week, we will meet to discuss ongoing and proposed projects,
`resources, and timing in preparation for the FY 2005 budget. Please review the attached Jist of projects and come to the
`meeting prepared to identify specific activities performed by you and your reports to support and/or execute each project.
`At this initial meeting we will focus on providing task details and timing required to complete projects that require 2 or
`more FTEs and identifying individuals needed for each task. Note that the MX projects are included in the list to serve as
`"markers" until substitute products are identified.
`
`PLAINTIFFS'
`TRIAL EXHIBIT
`PTX0255
`
`~
`
`EXHIBIT
`
`i D' 1'1-ddlb-IJ
`I o tv r ~.,~~
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX03470939
`
`PTX0255-00001
`
`1
`
`CIP2122
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`
`
`Sent:
`Recipient:
`
`Lehr Mary </O=CAR1ER-
`W ALLACE/OU=CRANMAJL/CN=RECIPIENTS/CN=EXCHANGE/CN=MLEHR>
`Tuesday, November 11, 2003 2:56:40 PM
`Balwani Gul <GBalwani@medpointepharma.com>;Cupo Frank
`<FCupo@medpointepharma. com>;Dang Grace <gdang@medpointeinc. com> ;He
`Weixuan <WHe@medpointepharma.com>;Mortko Henry
`<HMortko@medpointepharma.com>; Yayac Cindy <CYayac@medpointepharma.com>
`Cc:
`D'Addio Alex <ADAddio@medpointepharma.com>
`Subject:
`Wednesday Cough/Cold Meeting
`Attachments: Projects2.xls
`
`In place ofthe Wednesday Cough/Cold meeting this week, we will meet to discuss ongoing and proposed projects,
`resources, and timing in preparation for the FY 2005 budget. Please review the attached Jist of projects and come to the
`meeting prepared to identify specific activities performed by you and your reports to support and/or execute each project.
`At this initial meeting we will focus on providing task details and timing required to complete projects that require 2 or
`more FTEs and identifying individuals needed for each task. Note that the MX projects are included in the list to serve as
`"markers" until substitute products are identified.
`
`PLAINTIFFS'
`TRIAL EXHIBIT
`PTX0255
`
`~
`
`EXHIBIT
`
`i D' 1'1-ddlb-IJ
`I o tv r ~.,~~
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX03470939
`
`PTX0255-00001
`
`1
`
`CIP2122
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`
`
`Product and Process Development Projects
`
`Priority
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`1
`2
`2
`2
`2
`2
`2
`2
`2
`2
`2
`2
`2
`
`Project
`Astelin - Quality 0-B 5502BN Bottle Resin
`Astelin - Feasibility Study - V Bottom/Pump Placer
`Astelin - Evaluate NC08 Pump Actuator
`Astelin - Nasal Spray Reformulation
`Qualify Alternate Astelin NS Manufacturing and Testing Site
`Tussi-12D Suspension- Commitments to Compliance
`Update Tannate Drug Substance Assay- JFC Methods
`Preformulation Evaluation of Tannate Actives
`Sina-12X- Monltor Stability Programs
`Ryna-12X- Monitor Stability Programs
`Tussi-12X Suspension - Develop Formulation & Methods
`Tussi-12X Tablets- Develop Formulation & Methods
`Packaging Evaluation forT an nate Products
`Doral Tablets- Dissolution Profile Testing and Evaluation
`Depen - Qualify Manufacturing Site
`Optivar- Manufacturing Process Transfer Support
`Depen/Soma - Degradation Evaluation
`Astelin - Maintain Commercial Supply
`EZ Chrome Computer Validation (21 CFR 11)
`Cranbury GMP Compliant Operational Procedures (SOPs)
`Cranbury GMP Compliant Set-Up lQ/OQ/PQ Lab Equipment
`Cranbury GMP Compliant Training
`Astelin - Sample Package Fill Optimization
`Astelin - Qualify_ Calmar-Albert Pump
`Astelin - Transfer E:xtractables Method to Valois
`Quality - Support Site Audits
`Intellectual Property/Due Diligence/Tech Evai/Licensing
`Reference Standards Program
`Soma Sustained Release - Develop Formulation
`Modernize Decatur Analytical Methods
`Drug Substance Optimization
`Analytical Site Change Submission for Transferred Products
`Astelin- Full Pump Release Testing at Valois
`Astelin- Full Pump Release Testing at Calmar
`Decrease Phenylephrine Tannate Overage
`Anti-oxidant for Cough/Cold Products
`Optivar - Smaller Sample Size
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA APTX03470940
`
`PTX0255-00002
`
`2
`
`
`
`2
`2
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`3
`4
`4
`4
`4
`4
`4
`4
`4
`5
`5
`5
`5
`
`Astelin -Justify Removal of Nitrosamine Specification for Pump
`Soma 350 - Qualify Alternate Manufacturing Site
`Sina-12 MX Suspension - Feasibility Evaluation
`Sina-12 MX Tablets- Feasibility Evaluation
`Sina-12 MX Suspension - Develop Formulation and Methods
`Sina-12 MX Tablets- Develop Formulation and Methods
`Sina-12 MX Tablets- Transfer Process and Methods
`Sina-12 MX Suspension - Transfer Process and Method
`Ryna-12 MX Suspension - Feasibility Evaluation
`Ryna-1 2 MX Tablets- Feasibility Evaluation
`Ryna-12 MX Tablets- Transfer Process and Methods
`Ryna-12 MX Suspension- Transfer Process and Method
`Ryna-12 MX Suspension - Develop Formulation & Methods FY05
`Ryna-12 MX Tablets- Develop Formulation & Methods FY05
`Fluorofelbamate- Develop for IND
`Fluorofelbamate - Preformulation Evaluation
`Fluorofelbamate- IND and Scale-Up Support
`Dora! Tablets - Qualify New Drug Substance Supplier
`Fluorofelbamate - Develop And Evaluate Clinical Capsule Stability
`Tussi-12X Backup Suspension - Develop Formulation & Methods
`Tussi-12X Backup Tablets- Develop Formulation & Methods
`Astelin-D (Decongestant) - Feasibility Evaluation
`Soma - Lower Dose
`Astelin - Qualify 0-B Equistar Bottle Resin
`Facility/Lab/Office Management
`Dora! Tablets- Intermediate Dose
`Fluorofelbamate- Develop Tablet formulation
`Fluorofelbamate - Develop Pediatric Formulation
`Felbamate - Qualify Recrystallization (Orgamol)
`Soma 350 - DevelopNalidate New Deg Products Method
`Astelin - Investigate Elimination of BAC Adjustment Step
`Butisol - Validate Residual Acetone/ETAC Test Method
`Astelin NS/Steroid Combo - Feasibility of Dual Chamber
`Soma CC - Revise Current Dissolution Method
`Soma CC- DevelopNalidate New Deg Products Method
`Support Marketing (e.g., color change)
`Astelin - Develop Pediatric Product
`
`HIGHLY CONFIDENTIAL -
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA APTX03470940
`
`PTX0255-00003
`
`3
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
